Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $124.3 million.

  • Arrowhead Pharmaceuticals' Net Cash Flow rose 234.30% to $96.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.3 million, marking a year-over-year increase of 1101.89%. This contributed to the annual value of $124.3 million for FY2025, which is 1101.89% up from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Net Cash Flow is $124.3 million, which was up 1,101.89% from -$12.4 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Net Cash Flow's 5-year high stood at $124.3 million during FY2025, with a 5-year trough of -$76.4 million in FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was $3.0 million (2023), whereas its average is $38.3 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 512.33% in 2024, then soared by 1,101.89% in 2025.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Net Cash Flow stood at $40.9 million in 2021, then crashed by 286.53% to -$76.4 million in 2022, then skyrocketed by 103.94% to $3.0 million in 2023, then crashed by 512.33% to -$12.4 million in 2024, then spiked by 1,101.89% to $124.3 million in 2025.